Hennion & Walsh Asset Management Inc. Acquires 8,636 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX)

Hennion & Walsh Asset Management Inc. raised its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 18.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,385 shares of the company’s stock after acquiring an additional 8,636 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.12% of Pacira BioSciences worth $1,062,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Virtus Investment Advisers Inc. bought a new position in shares of Pacira BioSciences in the 3rd quarter valued at $98,000. State Street Corp raised its position in Pacira BioSciences by 5.8% in the third quarter. State Street Corp now owns 2,014,012 shares of the company’s stock valued at $30,311,000 after purchasing an additional 110,162 shares during the last quarter. Centiva Capital LP acquired a new stake in shares of Pacira BioSciences during the third quarter valued at about $398,000. PDT Partners LLC acquired a new stake in shares of Pacira BioSciences during the third quarter valued at about $3,469,000. Finally, Verition Fund Management LLC bought a new stake in shares of Pacira BioSciences during the third quarter worth about $493,000. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Price Performance

Shares of PCRX opened at $22.36 on Monday. The firm has a market cap of $1.03 billion, a PE ratio of -11.01 and a beta of 0.76. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $34.01. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. The business’s 50 day moving average price is $18.71 and its two-hundred day moving average price is $17.44.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Barclays cut their target price on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a research report on Tuesday, November 12th. Needham & Company LLC boosted their price objective on shares of Pacira BioSciences from $22.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, January 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and issued a $39.00 price target on shares of Pacira BioSciences in a research report on Wednesday, December 4th. Finally, Jefferies Financial Group raised their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, September 24th. Two investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Pacira BioSciences has an average rating of “Hold” and a consensus price target of $24.50.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.